The Spanish Group of Myelodysplastic Syndromes (GESMD) and the Spanish Society of Hematology and Hemotherapy (SEHH) have published the second edition of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Spanish Guidelines.

These guidelines are a reference for the diagnosis and prognosis of MDS and CMML for Spanish and Latin American hematologists. They are the result of 4 years of work by 97 authors, researchers, and clinicians.

"The guidelines are a way of transferring scientific advances in diagnostic techniques, clinical experiences and new treatments to the clinical setting and patient care," explains Francesc Solé, leader of the MDS Research Group at the Josep Carreras Research Institute and co-author of the guidelines. Blanca Xicoy, leader of the Myeloid Neoplasms Group at the Institute, has coordinated chapter 8, on CMML. Lurdes Zamora, co-leader of the same group, and Laura Palomo, of the MDS group, are the Institute's researchers who have participated as authors of the guidelines.